Nodular lymphocyte-predominant Hodgkin lymphoma represents an indolent yet biologically intriguing B-cell neoplasm. Clinicians often observe favorable outcomes with conservative management, but disease recurrence or aggressive transformation presents formidable challenges. Recent whole-transcriptome profiling has illuminated the complex NLPHL tumor microenvironment, demonstrating how surrounding non-neoplastic cells define disease progression. In this study, investigators systematically mapped the genomic continuum between nodular lymphoma and aggressive diffuse variants. Consequently, these findings offer vital mechanistic clues for practicing clinicians and pathologists worldwide.

Understanding the NLPHL Tumor Microenvironment and Disease Gradient

For decades, pathologists categorized nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich large B-cell lymphoma as related yet discrete clinical entities. However, genomic and transcriptomic studies reveal that these two neoplasms actually form a biological continuum. Classic forms of nodular lymphoma display a follicular framework packed with non-malignant mantle zone B lymphocytes. Conversely, advanced cases demonstrate a gradual depletion of these supportive mantle cells alongside marked histiocytic infiltration. Whole-transcriptome RNA sequencing of nearly two hundred patient specimens confirms this remarkable biological gradient. Therefore, researchers now view these conditions through the lens of microenvironmental evolution rather than rigid histopathologic boundaries. Furthermore, patient cohorts consistently validate this spectrum across geographic regions and clinical trial registries. When malignant lymphocyte-predominant cells alter their surroundings, they recruit distinct immune cell subsets that actively reshape local cytokine signaling. As a result, tumors shift from an indolent follicular architecture into an aggressive diffuse pattern. Clinicians must recognize this gradient because early biological shifts frequently dictate treatment failure. Thus, understanding microenvironmental remodeling helps oncologists identify high-risk individuals before overt clinical deterioration occurs.

Immunoarchitectural Patterns and Transcriptional Divergence

Histopathologists traditionally divide nodular lymphocyte-predominant Hodgkin lymphoma into classic and variant immunoarchitectural patterns based on tissue organization. Specifically, classic Fan patterns A and B display typical spherical nodular meshworks of follicular dendritic cells. In contrast, variant patterns C through F present diffuse, extranodular, or T-cell-rich microenvironments that mimic aggressive lymphomas. Transcriptomic profiling proves that variant immunoarchitectural patterns closely resemble T-cell/histiocyte-rich large B-cell lymphoma at the molecular level. Moreover, patients displaying these variant architectures frequently present with advanced clinical features, including splenic enlargement and elevated international prognostic scores. Consequently, the presence of variant histology serves as a dependable surrogate marker for aggressive microenvironmental restructuring. In addition, comparative pathway analyses demonstrate that classical patterns preserve normal B-cell receptor signaling and cell-cycle regulation networks. Variant cases, however, exhibit significant upregulation of pro-inflammatory cascades, matrix remodeling proteins, and systemic immune evasion pathways. Therefore, comprehensive tissue biopsies remain essential to capture these focal immunoarchitectural transformations. Pathologists must thoroughly examine multiple nodal sections to detect variant areas that might otherwise escape standard histopathologic surveillance.

Deconvoluting Cellular Composition Across the Lymphoma Spectrum

In-silico deconvolution of bulk RNA sequencing data provides unprecedented clarity regarding non-malignant immune infiltrates. In classic nodular disease, non-neoplastic polyclonal B cells predominate, constructing a dense and supportive follicular mantle network. However, as lymphomas transition toward variant patterns and full transformation, the cellular landscape undergoes dramatic reorganization. Variant patterns exhibit an intermediate cellular phenotype with declining B-cell fractions and increasing T-cell density. Furthermore, cases that transform into T-cell/histiocyte-rich large B-cell lymphoma demonstrate robust enrichment of activated CD4-positive helper cells, cytotoxic CD8-positive lymphocytes, and inflammatory macrophages. Interestingly, follicular helper T cells also exert a measurable impact on patient prognosis. Exploratory survival models link higher follicular helper T-cell content directly to shortened event-free survival. This counterintuitive finding indicates that specific T-cell subsets may sustain neoplastic cells through aberrant CD40 ligand stimulation or cytokine secretion. Meanwhile, the concurrent recruitment of tumor-associated macrophages fosters an inflammatory environment that facilitates tumor growth. Consequently, dissecting these cellular proportions provides valuable prognostic clues that surpass conventional clinical risk scores.

Immune Checkpoint Signatures and Prognostic Biomarkers

The immunological shift across the lymphoma spectrum directly modulates local immune checkpoint expression. Classical nodular cases demonstrate minimal checkpoint activation, reflecting an immunologically stable environment. In contrast, transformed cases and variant patterns exhibit prominent expression of PD-1, PD-L1, CTLA-4, and TIGIT checkpoints. Because cytotoxic T cells and macrophages dominate aggressive tumors, malignant cells upregulate inhibitory ligands to avoid immune destruction. Therefore, this pronounced immunosuppressive signature explains why transformed lymphomas frequently resist traditional immunochemotherapy protocols. Moreover, elevated checkpoint levels correlate closely with high Lymphocyte-Predominant International Prognostic Scores and systemic B symptoms. These molecular discoveries create an appealing biological rationale for evaluating targeted immune checkpoint inhibitors in refractory settings. In particular, dual checkpoint blockade or combination regimens targeting both macrophages and T cells could reverse microenvironmental exhaustion. Clinicians should monitor these emerging biomarkers to anticipate therapeutic responses and design rational salvage regimens. Thus, checkpoint quantification bridges basic laboratory biology with actionable bedside clinical decisions.

Translating Genomic Insights into Stratified Clinical Management

Modern management of nodular lymphocyte-predominant Hodgkin lymphoma requires tailored strategies that balance curative efficacy against long-term treatment toxicity. Patients with localized, classical histology often achieve excellent long-term remission with limited-field radiation therapy or active surveillance. However, clinicians cannot treat variant patterns and transformed cases with identical conservative measures. Because variant cases share transcriptomic programs with aggressive large B-cell lymphomas, these patients experience higher recurrence rates and worse progression-free survival. Consequently, oncologists frequently recommend systemic anthracycline-based chemoimmunotherapy for individuals harboring variant histology, splenic involvement, or adverse prognostic scores. Furthermore, the systematic identification of distinct microenvironmental signatures may soon replace non-specific chemotherapy regimens with precision immunotherapies. Integrating whole-transcriptome signatures into routine diagnostic workflows will enable pathologists to stratify patients accurately at initial biopsy. In addition, prospective clinical trials must evaluate whether checkpoint blockade can prevent early transformation in high-risk individuals. As clinical hematology adopts these molecular insights, risk-adapted management will ensure that every patient receives appropriately calibrated therapy.

What distinguishes classic NLPHL from variant immunoarchitectural patterns?

Classic patterns feature well-circumscribed, nodular B-cell follicles containing characteristic lymphocyte-predominant cells within dense mantle zone lymphocytes. Conversely, variant patterns show progressive mantle cell depletion, diffuse architecture, and prominent T-cell or histiocytic infiltration. Molecularly, variant patterns share significant transcriptional overlap with aggressive large B-cell lymphomas. Patients with variant patterns also experience higher clinical relapse rates, frequent splenic involvement, and worse overall outcomes than those with classic histology.

How does the tumor microenvironment influence clinical outcomes in these lymphomas?

The tumor microenvironment directly governs disease aggressiveness and treatment response. B-cell-rich microenvironments correlate with favorable, indolent disease courses and extended event-free survival. In contrast, microenvironments enriched with activated cytotoxic T lymphocytes, inflammatory macrophages, and exhausted follicular helper T cells correlate with aggressive disease behavior. These altered immune infiltrates express elevated immunosuppressive checkpoint molecules, blunting host anti-tumor responses and predisposing affected patients to early recurrence or aggressive histological transformation.

Why are immune checkpoint inhibitors being investigated for THRLBCL?

Whole-transcriptome profiling reveals that transformed lymphomas and variant patterns strongly upregulate inhibitory checkpoint genes, including PD-1, PD-L1, and TIGIT. These molecules induce profound functional exhaustion in surrounding cytotoxic lymphocytes and tumor-associated macrophages. Because conventional immunochemotherapy often fails to provide durable remissions in refractory cases, immune checkpoint inhibitors offer a biologically targeted mechanism to restore host anti-tumor immunity and effectively overcome the immunosuppressive tumor microenvironment.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. Kalashnikov I et al. Transcriptional landscape of nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich large B-cell lymphoma: tumor microenvironment and checkpoint genes. Haematologica. 2026 Nov 12. doi: 10.3324/haematol.2026.301728. PMID: 43016387.
2. Hartmann S, Eray M, Kube D, et al. Nodular lymphocyte predominant Hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma--endpoints of a spectrum of one disease? PLoS One. 2013;8(11):e78812.
3. Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022;36(7):1720-1748.